Nguyen Van-Nghia, Nguyen Cao Thuy Giang, Jeong Hyunsun, Truong Hoang Quan, Pham Binh T T, Bang Jieun, Koh Chang Woo, Kang Ji Hee, Lee Jeong Hyun, Wu Xiaofeng, Rhee Won Jong, Ko Young Tag, Swamy K M K, Park Sungnam, Park JaeHong, Shim Min Suk, Yoon Juyoung
Department of Chemistry and Nanoscience, Ewha Womans University, Seoul, 03760, Republic of Korea.
Department of Chemistry, School of Chemistry and Life Sciences, Hanoi University of Science and Technology, Ha Noi, 100000, Vietnam.
Adv Healthc Mater. 2025 Jul;14(18):e2500927. doi: 10.1002/adhm.202500927. Epub 2025 Apr 1.
Theranostic nanosensitizers with combined near-infrared (NIR) fluorescence imaging and sono-photodynamic effects have great potential for use in the personalized treatment of deep-seated tumors. However, developing effective nanosensitizers for NIR fluorescence image-guided sono-photodynamic therapy remains a considerable challenge, including the low generation efficacy of reactive oxygen species (ROS), poor photostability, and the absence of cancer specificity. Herein, a novel heavy atom-free nanosensitizer is developed, which exhibits intense NIR fluorescence, high ROS generation efficiency, and improved aqueous stability. By conjugating a bulky and electron-rich group, 4-(1,2,2-triphenylvinyl)-1,1'-biphenyl (TPE), to the IR820 backbone, the resulting IR820 bearing TPE (IR820-TPE) effectively generates ROS via type I and II photochemical mechanisms under 808 nm laser irradiation. Moreover, TPE conjugation considerably increases the sono-photodynamic performance of IR820. To improve the intracellular delivery and tumor-targeting ability of IR820-TPE, biotin-conjugated exosome (B-Exo) is used as a natural nanocarrier. In vitro studies demonstrate the outstanding therapeutic performance of IR820-TPE-loaded B-Exo (IR820-TPE@B-Exo) in synergistic sono-photodynamic cancer therapy. In vivo studies reveal that IR820-TPE@B-Exo shows enhanced tumor accumulation, strong fluorescence signals, and effective sono-photodynamic therapeutic activity with high biosafety. This work demonstrates that IR820-TPE@B-Exo is a promising sono-phototheranostic agent for safe and targeted cancer therapy and NIR fluorescence imaging.
具有近红外(NIR)荧光成像和超声光动力效应相结合的诊疗纳米敏化剂在深部肿瘤的个性化治疗中具有巨大潜力。然而,开发用于近红外荧光图像引导的超声光动力治疗的有效纳米敏化剂仍然是一个巨大的挑战,包括活性氧(ROS)生成效率低、光稳定性差以及缺乏癌症特异性。在此,开发了一种新型无重原子纳米敏化剂,其具有强烈的近红外荧光、高ROS生成效率和改善的水稳定性。通过将一个庞大且富电子的基团4-(1,2,2-三苯基乙烯基)-1,1'-联苯(TPE)连接到IR820主链上,所得的带有TPE的IR820(IR820-TPE)在808 nm激光照射下通过I型和II型光化学机制有效地产生活性氧。此外,TPE共轭显著提高了IR820的超声光动力性能。为了提高IR820-TPE的细胞内递送和肿瘤靶向能力,生物素共轭外泌体(B-Exo)被用作天然纳米载体。体外研究证明了负载IR820-TPE的B-Exo(IR820-TPE@B-Exo)在协同超声光动力癌症治疗中的出色治疗性能。体内研究表明,IR820-TPE@B-Exo显示出增强的肿瘤蓄积、强烈的荧光信号以及具有高生物安全性的有效的超声光动力治疗活性。这项工作表明,IR820-TPE@B-Exo是一种有前途的用于安全和靶向癌症治疗及近红外荧光成像的超声光诊疗剂。